Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OHB-607 versus standard neonatal care for prevention of severe bronchopulmonary dysplasia in extremely preterm infants
jRCT2031240339Phase 2Active, not recruiting
- Sponsor
- OHB Neonatology Ltd.
- Start
- Sep 2024
- Modality
- Recombinant Proteins and Enzymes
01
Overview
Phase 2, randomised, open-label trial of mecasermin rinfabate in bronchopulmonary dysplasia (BPD) (2 arms), sponsored by OHB Neonatology Ltd. Primary endpoint: Incidence of severe bronchopulmonary dysplasia or death by 36 weeks postmenstrual age. Started Sep 2024; status: active, not recruiting.
02
Drugs
mecasermin rinfabate
03
Conditions
bronchopulmonary dysplasia (BPD)
Beyond the preview
Go deeper on jRCT2031240339.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240339.